ATE114972T1 - Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen. - Google Patents

Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.

Info

Publication number
ATE114972T1
ATE114972T1 AT88106902T AT88106902T ATE114972T1 AT E114972 T1 ATE114972 T1 AT E114972T1 AT 88106902 T AT88106902 T AT 88106902T AT 88106902 T AT88106902 T AT 88106902T AT E114972 T1 ATE114972 T1 AT E114972T1
Authority
AT
Austria
Prior art keywords
icam
functional derivatives
treat non
specific inflammation
inflammation
Prior art date
Application number
AT88106902T
Other languages
English (en)
Inventor
Donald Carroll Anderson
Robert Rothlein
Clinton Wayne Smith
Randall Wilbur Barton
Original Assignee
Baylor College Medicine
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Boehringer Ingelheim Pharma filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE114972T1 publication Critical patent/ATE114972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88106902T 1987-11-02 1988-04-29 Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen. ATE114972T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11579787A 1987-11-02 1987-11-02

Publications (1)

Publication Number Publication Date
ATE114972T1 true ATE114972T1 (de) 1994-12-15

Family

ID=22363440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88106902T ATE114972T1 (de) 1987-11-02 1988-04-29 Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.

Country Status (10)

Country Link
EP (1) EP0314863B1 (de)
JP (1) JP2710627B2 (de)
AT (1) ATE114972T1 (de)
AU (2) AU1550988A (de)
CA (1) CA1331132C (de)
DE (1) DE3852374T2 (de)
DK (1) DK175491B1 (de)
ES (1) ES2064327T3 (de)
GR (1) GR3015298T3 (de)
ZA (1) ZA883160B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0387701B1 (de) * 1989-03-09 1992-08-12 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von interzellularen Adhäsions-Molekülen und deren Bindungsliganden bei der Behandlung von Asthma
JP3048632B2 (ja) * 1989-06-02 2000-06-05 ザ ジョーンズ ホプキンズ ユニヴァーシティ スクール オブ メディスン 白血球付着レセプターβ鎖に対するモノクローナル抗体と、この抗体の製造方法と、その応用
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
EP0468257B1 (de) * 1990-07-20 1999-09-01 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
JPH06501931A (ja) * 1990-08-31 1994-03-03 ベーリンガー・インゲルハイム・ファーマシュウティカルズ・インコーポレイテッド 抗接着性抗体を用いるエンドトキシンショックの治療法
AU9055091A (en) * 1990-11-08 1992-06-11 Biogen, Inc. Treatment for inflammatory bowel disease
HUT64476A (en) 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
EP0578819A4 (de) * 1992-01-27 1994-10-12 Icos Corp Icam ähnliche proteine.
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ES2103468T3 (es) * 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
AU3657893A (en) 1992-02-28 1993-09-13 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
DK0656789T3 (da) * 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
EP0757697A4 (de) * 1994-04-12 2000-05-17 Boehringer Ingelheim Pharma Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
RU2658015C2 (ru) 2012-07-25 2018-06-19 Саркоуд Байосайенс Инк. Ингибитор ассоциированного с функцией лимфоцитов антигена-1 (lfa-1), способы его получения и его полиморф

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.

Also Published As

Publication number Publication date
AU1550988A (en) 1989-07-27
DK239388A (da) 1989-05-03
DE3852374D1 (de) 1995-01-19
AU622120B2 (en) 1992-04-02
DK175491B1 (da) 2004-11-08
JP2710627B2 (ja) 1998-02-10
ZA883160B (en) 1990-02-28
EP0314863B1 (de) 1994-12-07
EP0314863A2 (de) 1989-05-10
JPH01135724A (ja) 1989-05-29
EP0314863A3 (en) 1990-04-04
DE3852374T2 (de) 1995-05-04
DK239388D0 (da) 1988-05-03
ES2064327T3 (es) 1995-02-01
AU2633388A (en) 1989-07-27
GR3015298T3 (en) 1995-06-30
CA1331132C (en) 1994-08-02

Similar Documents

Publication Publication Date Title
ATE114972T1 (de) Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE95064T1 (de) Verwendung von angiotensin-converting-enzyminhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
ATA696179A (de) Verfahren zur kontiuierlichen behandlung von stahlblechen
ATE58900T1 (de) Diaryldiazolylmethane.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
ATA364184A (de) Verfahren zur enzymatischen behandlung organischer stoffe und von biomasse
DE68907386D1 (de) Verwendung von phytinsaeure oder deren salzen zur verhinderung oder behandlung von lebererkrankungen.
BE891629A (fr) Promoteur de coagulation du sang et procede l'utilisant
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
AR230845A1 (es) Procedimiento para el tratamiento de sustratos de acero o de acero galvanizado
IT7923771A0 (it) Processo per il trattamento di acque di rifiuto contenenti cianuri e cianati.
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
DD131589A1 (de) Verfahren zur durchsatzbestimmung und-einstellung von f
SE422473B (sv) Forfarande for behandling av fosfaterat mjukt stal eller zinkbelagt mjukt stal

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time